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Five patients with ages ranging from 6 months to 3 years were analyzed. All received inhaled nitric oxide (NO - 20 parts per million
(ppm) ) and oxygen (02 - at a concentration of 90-95%) by means of an oxygen hood. Mean Pulmonary Artery Pressure (MPAP),
Mean Aortic Pressure (MAoP), Pulmonary Vascular Resistance (PVR) and Systemic Vascular Resistance (SVR) were measured and
the calculation of their relationship to pulmonary/systemic flow (Op/Os) was performed by the catheterization' of the femoral artery
vein. Three patients presented reduction in PVR and increase in Op/Os. There were no systemic alterations or any side effect from
using NO.
UNITERMS: Nitric Oxide - Pulmonary Hypertension- Congenital Cardiopathy.
INTRODUCTION
Pulmonary hypertension (PH) is associated with highmortality rate in several pathologies such asneonatal persistent pulmonary hypertension, acute
respiratory discomfort syndrome, in patients with chronic
obstructi ve pulmonary disease, and especially in the
immediate postoperative period after surgical correction
of congenital cardiopathies which are accompanied by
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PH (I). Pulmonary hypertension contributes to the
worsening of hypoxemia and overload of the right
ventricle. These cardiopathies lead to hypertrophy and
hyperplasia of the vascular musculature and consequent
vasoconstriction. Conventional treatment after, surgery
consists of using hyperventilation, alkalization, increase
in the inhaled oxygen fraction, inotropics and vasodilators.
The great advantage in using inhaled nitric oxide
(NO) is that, contrary to systemic vasodilators, it only
reaches the ventilated alveoli, thereby causing selective
pulmonary vasodilation (2,3) with deviation of the flow
to these areas, thus improving oxygenation and
intrapulmonary shunt, in a manner similar to what occurs
with the use of high oxygen concentrations in the
evaluation prior to surgery, during catheterization.
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Table I
Diagnosis of cardiopathies and age range of 5
patients submitted to inhaled NO and oxygen at high
concentrations.
Our main objective was to verify whether inhaled
NO is a safe procedure for patients with congenital
cardiopathies and for the professional group involved
in its application. As a secondary objective, we
compared inhaled NO with the administration of
oxygen concentrations close to 100%, observing
alterations in the mean pulmonary artery pressure
(MPAP), mean aortic pressure (MAoP), pulmonary
vascular resistance (PVR), systemic vascular resistance
(SVR) and the relationship of pulmonary/systemic flow
(Qp/Qs) during the preoperative phase, for pediatric
patients with congenital cardiopathy and PH.
Case
2
3
4
5
Age
2 years
2 years
1 year
3 years
6 months
Cardiopathy
Interventricular communication,
Aortic insufficiency.
Ostio atrium-ventricularis comunis
Interventricular communication
Interventricular communication,
Persistence of the arterial canal
Interventricular and interatrial
communication
PATIENTS AND METHODS
RESULTS
Figure 1 - Alterations in pulmonary vascular resistance (PVR)
during inhalation of NO (20 ppm) and oxygen at high
concentrations.
In this study we could observe, as shown in Figure 1,
that patients 1, 2 and 5 presented a decrease in pulmonary
vascular resistance using NO at 20 ppm similar to the result
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During NO inhalation, the inhaled oxygen fraction was
maintained at a level of 40% to 50%. Monitoring of NO
and nitrogen dioxide (N02) was performed with a Bedfont
EC90 monitor (Bedfont Scientific Ltd); monitoring of the
inhaled fraction of oxygen was performed through a
MiniOX III monitor (Catalyst Research), placed close to
the patient's nostril.
This study was carried out with the approval of the
Medical Ethics Committee of the Sao Paulo Hospital.
Criteria for participation in this study were children below
13 years with congenital cardiopathy and who presented
pulmonary hypertension with MPAP > 25 mmHg, before
surgical correction. The sample consisted of 5 patients
presenting several types of cardiopathies and ages ranging
from 6 months to 3 years, as shown in Table 1. All patients
presented pulmonary hypertension by intracardiac shunt.
The children were submitted to catheterization
through cannulation of the femoral artery. Hemodynamic
measurements of the aortic'pressure (mmHg), pulmonary
artery (mmHg) and right atrium (mmHg), and
measurements of pulmonary and systemic vascular
resistances (Wood units), and pulmonary (Qp) and
systemic (Qs) flows, were obtained by a standard formula,
where the flow is the ratio between the oxygen
consumption and the difference in the arterial and venous
oxygen content (Q = V02 /Ca02 -Cv02, where V02 =
oxygen consumption; Ca02 = arterial oxygen content;
Cv02 = Venous oxygen content). These measurements
were obtained in. three phases: basal, with 10 minutes of
oxyge~, inhalation, and 5 minutes of NO inhalation at a
concentration of 20 parts per million (ppm).
During the procedure, the patients were sedated with
midazolam, intravenous (IV) at a dosage of 0.1 mg/kg, .
and breathed room air spontaneously. For inhalation, an
oxygen hood with a 15 L/min oxygen flow reaching
concentrations between 90% to 95% was used for 10
minutes. NO was applied using a cylinder with a mixture
of nitric oxide and nitrogen (NO/N2) of 1000 ppm. The
gas entered the circuit and mixed with oxygen at a flow
of 51/min just before ~he entrance of the hood (Fig. 1).
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Figure 2 - Alterations in the relationship pulmonary/systemic flow
(Qp/Qs) during inhalation of NO (20 ppm) and oxygen
at high concentrations.
obtained with oxygen inhaled in high concentrations. An
increase in the relationship of pulmonary to systemic flow
(Qp/Qs) was observed in two patients with 02 and only
one with NO, as shown in Figure 2.
Regarding systemic alterations, there was no fall in
vascular resistance or in aortic pressure when using NO
(Figure 3).
The concentration of nitrogen dioxide (N02) varied
from 0 to 0.4 ppm in the interior of the oxygen hood while
in the procedure room (total area 12m2) the concentration
of NO varied from 0 to 5 ppm and N02 was not detectable.
In addition, we did not observe any symptomatology
in the professional workers (headache or vomit) related
to the inhaled NO.
DISCUSSION
There are now several studies(4,5) which have
demonstrated that the clinical use of inhaled NO is a safe
procedure as long as some precautions are taken: training
of the professional group responsible for utilization of the
gas, and constant monitoring of NO/N02 concentrations
as well as the levels of metahemoglobinemia. According
to the Institute of Occupational Security and
Administration of Health of the United States (6), the limit
fixed for exposure to NO is 25 ppm, when inhaled for 8
hours/day, and that of N02 is 5 ppm. In this study, the
formation of N02 in the interior of the oxygen hood did
not surpass 0.4 ppm, it was not detectable in the procedure
room, and the concentration of NO in the room did not
exceed 5 ppm; all these values are considered highly
acceptable.
Figure 3 - Alterations in the mean aortic pressure (PAoP) during
inhalation of oxygen at high concentrations and NO (20
ppm).
In our experiment NO proved to be-an easy-to-use
substance and we did not observe any immediate
complication or any side-effect during the procedure.
None of the professional workers presented any
symptomatology (headache or vomit).
Data in the literature (7,8,9) have demonstrated the role
of inhaled NO for decreasing PVR and improving the
oxygenation of patients in the pre- and postoperative
periods of pediatric surgical correction. Roberts et a1.\5)
observed a significant reduction in pulmonary vascular
resistance, using inhaled NO during catheterization or
preoperative evaluation in children with congenital heart
diseases and PH; and he did not observe systemic
hypotension or significant increases in the levels of
metahemoglobinemia.
Although in our initial experience with on small
sample of 5 patients, no statistically significant differences
were observed regarding the fall of PVR when using
inhaled NO as compared to basal data, we observed that
three of these patients had a significant fall in PVR and
an increase in the relationship Qp/Qs, similar to that
obtained by using oxygen in high concentrations (90 to
95%). These results indicate that NO at 20 ppm was able
to provoke dilation of the pulmonary vascular smooth
musculature without causing significant systemic changes,
since we observed that the values of SVR remained
unaltered and very close to those measured during the
basal phase, in accordance with what has been reported
in many clinical studies (4,5).,Oxygen at high concentrations
may become a h~ghly toxic gas leading to severe
pulmonary disturbances such as atelectasis, mucous
dryness and especially cytotoxic lesions with pulmonary
edema and respiratory insufficiency (10).
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